U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 10:03:37 UTC 2023
Edited
by admin
on Sat Dec 16 10:03:37 UTC 2023
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
L0423Z5LDW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2C8
Common Name English
HUMAN CYTOCHROME P450 2C8
Common Name English
CYTOCHROME P 450 2C8
Common Name English
CYP2C8
Common Name English
CYP-2C8
Common Name English
CYP2C8 (HUMAN)
Common Name English
Code System Code Type Description
UNIPROT
P10632
Created by admin on Sat Dec 16 10:03:47 UTC 2023 , Edited by admin on Sat Dec 16 10:03:47 UTC 2023
PRIMARY
CAS
330207-13-1
Created by admin on Sat Dec 16 10:03:47 UTC 2023 , Edited by admin on Sat Dec 16 10:03:47 UTC 2023
PRIMARY
FDA UNII
L0423Z5LDW
Created by admin on Sat Dec 16 10:03:47 UTC 2023 , Edited by admin on Sat Dec 16 10:03:47 UTC 2023
PRIMARY
Related Record Type Details
Structure of MALATHION
INHIBITOR -> METABOLIC ENZYME
Human hepatic CYP2C8 activities after incubation with different pesticides showed that CYP2C8 activities were inhibited extensively by malathion (100,90%).
Structure of TOZASERTIB
SUBSTRATE -> METABOLIC ENZYME
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of GRAZOPREVIR ANHYDROUS
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of VANOXERINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of VOXILAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of DASABUVIR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of SELEXIPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of ROSIGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ZOPICLONE
SUBSTRATE -> METABOLIC ENZYME
Structure of SIPOGLITAZAR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
Structure of TECOVIRIMAT
INHIBITOR -> METABOLIC ENZYME
MINOR
Structure of DRONEDARONE
INHIBITOR -> METABOLIC ENZYME
LOW
Ki
Structure of IMATINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of APOMORPHINE
SUBSTRATE -> METABOLIC ENZYME
Structure of Desloratadine
SUBSTRATE -> METABOLIC ENZYME
Structure of DUVELISIB
INHIBITOR -> METABOLIC ENZYME
Structure of OLACAFTOR
INHIBITOR -> METABOLIC ENZYME
Structure of SERATRODAST
SUBSTRATE -> METABOLIC ENZYME
Structure of VELPATASVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of CERLAPIRDINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of GEMFIBROZIL
INHIBITOR -> METABOLIC ENZYME
MAJOR
IC50
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of DOSIMERTINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of SILIBININ A
SUBSTRATE -> METABOLIC ENZYME
Structure of Desloratadine
NON-INHIBITOR -> METABOLIC ENZYME
Structure of GLECAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of REPAGLINIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of AMIODARONE
SUBSTRATE -> METABOLIC ENZYME
Structure of CLOPIDOGREL ACYL-.BETA.-D-GLUCURONIDE
INHIBITOR -> METABOLIC ENZYME
Structure of VECABRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of JD-5037
INHIBITOR -> METABOLIC ENZYME
Structure of PHENOBARBITAL
INDUCER -> METABOLIC ENZYME
Structure of LONAFARNIB
SUBSTRATE -> METABOLIC ENZYME
Structure of EVATANEPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of Taragarestrant
INHIBITOR -> METABOLIC ENZYME
Structure of AZD-1656
SUBSTRATE -> METABOLIC ENZYME
Structure of ISAVUCONAZOLE
INDUCER -> METABOLIC ENZYME
Structure of ALVESPIMYCIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of LURASIDONE
INHIBITOR -> METABOLIC ENZYME
MODERATE
Structure of PRALSETINIB
INDUCER -> METABOLIC ENZYME
Structure of TAZAROTENIC ACID
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENTHOATE
INHIBITOR -> METABOLIC ENZYME
Human hepatic CYP2C8 activities after incubation with different pesticides showed that CYP2C8 activities were inhibited extensively by phenthoate (100,90%).
Structure of CENOBAMATE
INDUCER -> METABOLIC ENZYME
Structure of METHADONE
SUBSTRATE -> METABOLIC ENZYME
Structure of SEBETRALSTAT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of SELEXIPAG
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of OXYMETAZOLINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of ORANTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of TERIFLUNOMIDE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of COBICISTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of IROSUSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of REGORAFENIB ANHYDROUS
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of SIMEPREVIR
INHIBITOR -> METABOLIC ENZYME
CYP2C8
IC50
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of ELISMETREP
INHIBITOR -> METABOLIC ENZYME
Structure of ETHINYL ESTRADIOL
SUBSTRATE -> METABOLIC ENZYME
Structure of TRIMETHOPRIM
INHIBITOR -> METABOLIC ENZYME
MAJOR
Ki
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of ISAVUCONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of ACT-333679
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of METHOXYCHLOR
SUBSTRATE -> METABOLIC ENZYME
Structure of GLASDEGIB
SUBSTRATE -> METABOLIC ENZYME
Glasdegib is metabolized primarily by the CYP3A4 pathway, with minor contributions by CYP2C8 and UGT1A9
MINOR
Structure of TRICLABENDAZOLE SULFOXIDE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CERIVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CLASCOTERONE
INHIBITOR -> METABOLIC ENZYME
clascoterone cream, 1%, has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4.
IC50
Structure of PROPANAMIDE, N-(5-(2-(2-METHOXY-3-PYRIDINYL)-7-METHYLIMIDAZO(1,2-A)PYRIDIN-3-YL)-6-(2-(1-METHYL-6-ISOQUINOLINYL)ETHYNYL)-2-PYRIDINYL)-2-(METHYLAMINO)-, (2S)-
INHIBITOR -> METABOLIC ENZYME
Structure of CABAZITAXEL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of BREXPIPRAZOLE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of RIOCIGUAT
SUBSTRATE -> METABOLIC ENZYME
Structure of BUPRENORPHINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PRALSETINIB
INHIBITOR -> METABOLIC ENZYME
Structure of FLIBANSERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLOROQUINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RIPRETINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
MINOR
Structure of DEFERASIROX
INHIBITOR -> METABOLIC ENZYME
WEAK
IC50
Structure of TUCATINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of LOMITAPIDE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ELAGOLIX
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TEPOTINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of AMODIAQUINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ISTRADEFYLLINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of OZANIMOD
SUBSTRATE -> METABOLIC ENZYME
Structure of LORLATINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PACLITAXEL
SUBSTRATE -> METABOLIC ENZYME
Structure of ELTROMBOPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of LICOFELONE
SUBSTRATE -> METABOLIC ENZYME
Structure of UMBRALISIB
INHIBITOR -> METABOLIC ENZYME
Structure of FINERENONE
SUBSTRATE -> METABOLIC ENZYME
Structure of Tuspetinib
INHIBITOR -> METABOLIC ENZYME
Structure of OTESECONAZOLE
INDUCER -> METABOLIC ENZYME
mRNA levels in at least 2 hepatocyte cultures. Up 10 micromolar OTESECONAZOLE
Structure of SARIZOTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of ABIRATERONE
INHIBITOR -> METABOLIC ENZYME
In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
Structure of RELUGOLIX
SUBSTRATE -> METABOLIC ENZYME
Structure of SILIBININ A
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of SIMEPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-06835919
NON-INHIBITOR -> METABOLIC ENZYME
Structure of LUMATEPERONE
SUBSTRATE -> METABOLIC ENZYME
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
SUBSTRATE -> METABOLIC ENZYME
Structure of TRIFAROTENE
SUBSTRATE -> METABOLIC ENZYME
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of RETAPAMULIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
Structure of IDELALISIB
INHIBITOR -> METABOLIC ENZYME
IN VITRO
Structure of ALDUMASTAT
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of TUCATINIB
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Structure of RIVOGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of TAFENOQUINE
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of MONTELUKAST
SUBSTRATE -> METABOLIC ENZYME
Structure of DABRAFENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of GS-563117
INHIBITOR -> METABOLIC ENZYME
Structure of BRIGATINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ALECTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORAMPHENICOL
NON-INHIBITOR -> METABOLIC ENZYME
Structure of RIFAMYCIN
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of OLODATEROL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TRICLABENDAZOLE SULFONE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of MOMELOTINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ENZALUTAMIDE
SUBSTRATE -> METABOLIC ENZYME
In vivo, the sum of enzalutamide and M2 exposure was increased by 2.2-fold and 1.3-fold when it was co-administered with gemfibrozil (strong CYP2C8 inhibitor) or itraconazole (strong CYP3A4 inhibitor), respectively. If the co-administration of enzalutamide with a strong CYP2C8 inhibitor cannot be avoided, the daily enzalutamide dose should be reduced to 80 mg.
Structure of UAB-30
SUBSTRATE -> METABOLIC ENZYME
Structure of Migoprotafib
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
IC50
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of TIRBANIBULIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of MITAPIVAT
INDUCER -> METABOLIC ENZYME
More than two-fold increase in mRNA expression concentration dependence. Use of mitapivat should be avoided with substrates of CYP3A, CYP2B6, or CYP2C that have narrow therapeutic index.
Structure of LONAFARNIB
INHIBITOR -> METABOLIC ENZYME
Structure of CARBAMAZEPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of AVATROMBOPAG
INDUCER -> METABOLIC ENZYME
In vitro data suggests that avatrombopag weakly induces CYP2C8 and CYP2C9
WEAK
Structure of LENVATINIB
INHIBITOR -> METABOLIC ENZYME
INHIBITOR
PLASMA
Structure of PROFENOFOS
INHIBITOR -> METABOLIC ENZYME
inhibitions between 59 and 84% were observed with profenofos
Structure of TAMATINIB
INDUCER -> METABOLIC ENZYME
Structure of MAVOGLURANT
SUBSTRATE -> METABOLIC ENZYME
Structure of APALUTAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of OTESECONAZOLE
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
IC50
Structure of AZILSARTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of CERALASERTIB
SUBSTRATE -> METABOLIC ENZYME
Structure of PRETOMANID
INHIBITOR -> METABOLIC ENZYME
Pretomanid is a weak time-dependent inhibitor of CYP2C8 and CYP2C19.
TIME-DEPENDENT INHIBITION
Structure of ELAGOLIX
INDUCER -> TARGET
Structure of RHINACANTHIN C
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of PEXIDARTINIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of VERINURAD
SUBSTRATE -> METABOLIC ENZYME
Structure of Belumosudil
SUBSTRATE -> METABOLIC ENZYME
Based on in vitro assessment, CYP3A4 (41.9%) was the predominant cytochrome P450 (CYP) isoform responsible for the metabolism of belumosudil although CYP2D6 (21.7%), CYP2C8 (14.2%), CYP1A2 (<5%), CYP2C19 (<5%), and UGT1A9 may also contribute to a lesser extent
Structure of ZIMLOVISERTIB
NON-INHIBITOR -> METABOLIC ENZYME
Structure of FENITROTHION
INHIBITOR -> METABOLIC ENZYME
inhibitions between 59 and 84% were observed with fenitrothion
Structure of ELAGOLIX
INHIBITOR -> TARGET
Ki
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966